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Eur J Vasc Endovasc Surg (2016) 51, 1e2EDITORIALIntra-arterial Therapy in the Early Treatment of Acute Ischaemic StrokeIn 1995, intravenously administered recombinant tissue-
type plasminogen activator (rtPA) was demonstrated to
be effective as a treatment for acute ischaemic stroke
provided it was commenced within 3 hours of stroke onset.1
In 2008, the ECASS-2 trial demonstrated that the time
window for intravenous thrombolysis could be increased to
4.5 hours.2 More recently, intra-arterial thrombectomy
(IAT), in addition to intravenous rtPA, has been shown to be
highly beneﬁcial when administered within 6 hours after
acute stroke onset in six randomized clinical trials.3e8 A
meta-analysis of these trials shows an absolute risk differ-
ence of 19% for achieving a good outcome (modiﬁed Rankin
score 0-2) in favour of IAT. The corresponding pooled odds
ratio was 2.30 with 95% conﬁdence intervals of 1.82e2.89.
(Fig. 1).
For several reasons, the establishment of IAT as an
evidence-based treatment is a historic breakthrough in the
neurovascular ﬁeld. Firstly, after intravenously administered
rtPA was demonstrated to be effective, it took stroke re-
searchers another 20 years to develop another beneﬁcial
therapeutic strategy for use in the ﬁrst hours after onset of
ischaemic stroke. What is perhaps more surprising is that
IAT for acute ischaemic stroke had been shown to be
feasible 30 years earlier.9 Secondly, ﬁve trials demonstrating
identical positive results for IAT have now been published
within a timeframe of only 6 months. No other intervention
in the cardiovascular ﬁeld has been considered so impor-
tant that the editors of the New England Journal of Medi-
cine decided to publish the results of ﬁve trials on the same
topic in the same volume. Finally, three other well-designed
randomized controlled trials of endovascular recanalization
therapies published in 2013 did not demonstrate improved
clinical outcomes after intra-arterial intervention.10e12 The
failure of these three trials may be explained by the use of
ﬁrst-generation devices, whereas in the more recent posi-
tive trials, most were treated with newer generation de-
vices, including stent retrievers. In addition, the positive
trials had prerequisites in their inclusion criteria including
the documentation of an occluded large intracranial artery
on CT-angiography or a relative large penumbra on CT-
perfusion, both increasing the chances of a good outcome
after recanalization.
The implementation of IAT will require substantial
changes in the organization of acute stroke services. A
dedicated stroke team will now have to be available 24/7,1078-5884/ 2015 European Society for Vascular Surgery. Published by
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http://dx.doi.org/10.1016/j.ejvs.2015.07.022not only for intravenous but also for intra-arterial therapy.
CT scanning facilities, angiography suites and their
personnel will have to be available within minutes of the
patient arriving and peripheral hospitals will have to
develop robust referral and transfer protocols to regional
neurointervention centres if necessary. Neurointervention
centres should expect to have to treat more patients than
before and they should anticipate the need for aggressive
implementation of secondary prevention measures after
successful IAT.
The introduction of IAT may also increase the need for
expedited carotid interventions such as endarterectomy or
stenting. It may be challenging for interventionists to stent a
severe stenosis of the extracranial carotid artery at the
same time as they treat an occluded intracranial artery.
From a pragmatic point of view, this may seem a good
approach, but it is unknown if the patient will beneﬁt from
a simultaneous procedure, or if it would be better to
perform deferred carotid surgery after a few days. In the Mr
Clean study, additional carotid interventions were per-
formed in one out of eight patients (13%) who were treated
with thrombolysis.3 It is well known that carotid endarter-
ectomy should be performed within a few days after onset
of a TIA or minor disabling stroke, but we know little about
the safety of this procedure in patients with a severe carotid
artery stenosis who only very recently suffered from a
major stroke that was successfully treated with IAT. Expe-
dited carotid surgery within 24 hours of lysis completion has
shown promising results,13 but more data on stenting
versus surgery and especially the optimal timing are still
required.
Endovascular treatment in posterior circulation stroke
patients is less well studied than in the anterior circula-
tion. Possibly, patients can be treated at a later time
because the posterior circulation has a better collateral
supply. Patients with basilar artery occlusion have a bad
prognosis and it is, therefore, tempting to predict that IAT
will become the ﬁrst-line treatment in patients with basilar
artery occlusion. Hopefully this will be answered by the
ongoing Basilar Artery International Cooperation Study
(BASICS).14
In addition, it is possible that imaging strategies in the
hyper-acute period may have to be modiﬁed to include a
follow-up examination, because fresh occlusions can rapidly
change. It has been shown recently that acute symptomatic
occlusion of the extracranial carotid artery may spontane-
ously recanalize in the early hours/days after stroke onset.
In a large series of patients with an acute ischaemic stroke
that followed carotid occlusion, conversion to a high-grade
Figure 1. Pooled results for good outcome (deﬁned as modiﬁed Rankin score [mRS] 0-2) in randomized clinical trials testing intra-arterial
(IA) therapy in the early stage of ischaemic stroke (courtesy Dr A. Algra).3e8
2 EditorialICA stenosis at second imaging was observed in 16% of
patients.15 This suggests that follow-up imaging is appro-
priate in patients with a residual carotid occlusion after IAT
in whom carotid endarterectomy might become beneﬁcial
after early spontaneous recanalization.
Despite the welcome success of IAT in the recent trials,
many questions remain. What will be the role of collaterals
visualized with CT angiography in the acute stage and how
should one deal with the volume of the infarct core and its
surrounding penumbra on CT perfusion imaging? What is
the maximal time window for IAT? Is it now appropriate to
treat patients with “wake up” strokes or patients with an
ischaemic stroke that is 9e12 hours old, provided they have
a good collateral blood supply? Is it necessary to perform
IAT always in combination with intravenous thrombolysis,
which is otherwise associated with a 6% risk of intracranial
haemorrhage, or would it be better to simply aim for im-
mediate intra-arterial therapy? Will it be necessary to
perform new randomized clinical trials to compare stent
retrievers with newer devices that can remove fresh
thrombus by means of aspiration?
In summary, 2015 will be remembered as the year in
which IAT was established as a highly beneﬁcial therapy for
patients with acute ischaemic stroke affecting the anterior
circulation. Stroke teams should now move to implement
IAT in their treatment strategies and adapt their organiza-
tion accordingly. More knowledge about the best in-
dications for IAT and the need for additional carotid
interventions will be forthcoming in the future.
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